Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 101 - 125 of 792 in total

Bempedoic acid

High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are...
Approved
Investigational
Matched Description: … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased ... , 2020. ... genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and …
Matched Categories: … bempedoic acid and ezetimibe …

CVac

Approved
Investigational
Matched Synonyms: … Autologous dendritic cells pulsed with recombinant human fusion protein (MUCIN1 and Glutathione S Transferase …

Citric acid

A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA...
Approved
Nutraceutical
Vet approved
Matched Description: … active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020 …
Matched Mixtures name: … Up and Up Antacid and Pain Relief ... Sodium Citrate and Citric Acid ... Effervescent Antacid and Pain Relief …
Matched Categories: … Alimentary Tract and Metabolism …

Ripretinib

Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … by the FDA on May 15, 2020. ... stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Satralizumab

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … [eculizumab] in June 2019 and [inebilizumab] in June 2020). ... by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … 2020 for the same indication. ... [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous ... Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March …
Matched Categories: … Sex Hormones and Insulins …

Polatuzumab vedotin

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … approved by Health Canada on July 9, 2020. ... humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Dutasteride

Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal...
Approved
Investigational
Matched Description: … hormonal mediator that plays a role in the development and enlargement of the prostate gland. ... [A1909] Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary ... 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and …
Matched Mixtures name: … Dutasteride and tamsulosin hydrochloride ... Dutasteride and Tamsulosin Hydrochloride ... Dutasteride and tamsulosin hydrochloride …
Matched Categories: … tamsulosin and dutasteride ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lactitol

Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. sucrose). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides...
Approved
Investigational
Matched Description: … powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020 ... [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet ... [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other …
Matched Categories: … Diet, Food, and Nutrition ... Alimentary Tract and Metabolism …

Collagenase clostridium histolyticum

Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. On July 6,...
Approved
Investigational
Matched Description: … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA ... It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and ... [L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and …
Matched Categories: … Enzymes and Coenzymes ... Skin and Mucous Membrane Agents ... Preparations for Treatment of Wounds and Ulcers …

Chloroquine

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a...
Approved
Investigational
Vet approved
Matched Description: … of COVID-19 was revoked on 15 June 2020. ... treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and ... of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis …
Matched Categories: … chloroquine and proguanil ... Antiparasitic Products, Insecticides and Repellents …

Darunavir

Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. Darunavir is being...
Approved
Matched Description: … [A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] …
Matched Categories: … darunavir and ritonavir ... darunavir and cobicistat ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat …
Matched Products: … Darunavir 600 and 800 mg …

Setmelanotide

Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Description: … on November 25, 2020. ... [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval ... agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Remimazolam

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational
Matched Description: … was approved for use by the FDA in July 2020 under the brand name Byfavo. ... thus susceptible to rapid biotransformation and elimination as inactive metabolites. ... Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Apadamtase alfa

Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. Patients with cTTP...
Approved
Investigational
Matched Synonyms: … Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs …
Matched Description: … rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ... Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and ... thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... apadamtase alfa and cinaxadamtase alfa …

Tirbanibulin

Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic ... Tirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for ... Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. …

Berotralstat

Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to...
Approved
Matched Description: … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral ... therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. ... activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and …
Matched Categories: … Blood and Blood Forming Organs …

Drostanolone propionate

Approved
Illicit
Matched Categories: … Testosterone and derivatives …

Cedazuridine

Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous...
Approved
Investigational
Matched Description: … was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by Astex ... treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells. ... [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020 ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Sacituzumab govitecan

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European ... Commission and Health Canada respectively. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020 ... Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Potassium

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium)...
Approved
Experimental
Matched Description: … It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for ... dextrose and sodium chloride. ... [A186928] Many conditions and diseases interfere with normal body potassium balance, and underconsumption …
Matched Mixtures name: … CALCIUM AND MAGNESIUM PLUS C,POTASSIUM AND ZINC TABLET ... Potassium and Iodine Tab ... Revit Multi-vitamins and Minerals …
Matched Categories: … mefruside and potassium ... clopamide and potassium ... clofenamide and potassium ... furosemide and potassium ... quinethazone and potassium …

Gibberella fujikuroi

Gibberella fujikuroi allergenic extract is used in allergenic testing.
Approved
Matched Synonyms: … Molds, rusts and smuts, fusarium moniliforme …

Rozanolixizumab

Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … , and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020 ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 101 - 125 of 792 in total